Last reviewed · How we verify
Sorafenib + Pravastatin
This combination pairs sorafenib, a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, with pravastatin, a statin that may enhance anti-tumor effects and reduce cardiovascular risk.
This combination pairs sorafenib, a multi-kinase inhibitor that blocks tumor cell proliferation and angiogenesis, with pravastatin, a statin that may enhance anti-tumor effects and reduce cardiovascular risk. Used for Advanced hepatocellular carcinoma (investigational combination).
At a glance
| Generic name | Sorafenib + Pravastatin |
|---|---|
| Also known as | 800 mg of sorafenib twice daily oral doses associated with, 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner. |
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Drug class | Multi-kinase inhibitor + HMG-CoA reductase inhibitor |
| Target | RAF, VEGFR, PDGFR (sorafenib); HMG-CoA reductase (pravastatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Sorafenib inhibits multiple receptor tyrosine kinases (RAF, VEGFR, PDGFR) and serine/threonine kinases to suppress tumor growth and tumor-associated angiogenesis. Pravastatin, a HMG-CoA reductase inhibitor, lowers cholesterol and may have pleiotropic anti-inflammatory and anti-angiogenic properties that complement sorafenib's mechanism. The combination is hypothesized to improve efficacy while managing sorafenib-associated cardiovascular toxicity.
Approved indications
- Advanced hepatocellular carcinoma (investigational combination)
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Fatigue
- Hypertension
- Muscle pain or myopathy
Key clinical trials
- Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma (PHASE3)
- Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis (PHASE3)
- Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma (PHASE2)
- Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib + Pravastatin CI brief — competitive landscape report
- Sorafenib + Pravastatin updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Dijon portfolio CI